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A76-year-old woman with unexplained hypoxemia and severe exertional dyspnea wasadmitted to our department. The symptoms had appeared during tamoxifen therapyafter resection of breast carcinoma; history revealed recurrent upper gastrointestinal
bleeding, epistaxis, and a granddaughter deceased because of a cerebral arteriovenous malfor-
mation. Chest computed tomography scan showed the presence of a highly vascularized nodule
in the right lower lobe.
Right pulmonary artery angiography demonstrated a large pulmonary arteriovenous malforma-
tion (PAVM) (Online Video 1) with massive right-to-left shunt (A, B, C; Online Video 2); this
confirmed the diagnosis of hereditary hemorrhagic telangiectasia (1). The arrows point to the
right upper pulmonary vein.
We decided to percutaneously close the PAVM. An occlusion test was performed before the
procedure (D); O2 saturation rose from 87% to 96%. The PAVM was subsequently closed using
a vascular occlusion device (E) with complete abolishment of the right-to-left shunt (F; Online
Video 3). It is likely that selective estrogen receptor modulator therapy may have been responsible
for the enlargement of the PAVM in our patient (2).
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